Furthermore, BTN3A1 is detected in CRC at the tumor site, on epithelial and stromal cells, often close to areas infiltrated by Vδ2 T lymphocytes, making conceivable the use of N-BPs in therapeutic schemes against CRC [19]. This evidence concerns the gene BTN3A1 and neoplasm.